Biotech Stocks Facing FDA Decision In May


A panel of outside experts convened by the FDA will vote on Achaogen Inc.’s (AKAO) Plazomicin on May 2, 2018.

Plazomicin IV is proposed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and bloodstream infections (BSI) due to certain Enterobacteriaceae in patients who have limited or no alternative treatment option.

The FDA’s final decision on Plazomicin is expected on June 25, 2018.

If approved, Plazomicin could contribute $313 million in peak sales by 2022, according to market research firm EvaluatePharma.

AKAO closed Friday’s (Apr.27) trading at $13.09, up 1.32%.